Continuation of afatinib (A) beyond progression: results of a randomized, open-label, phase III trial of A plus paclitaxel (P) versus investigator's choice chemotherapy (CT) in pa…
M Schuler, D Planchard, JC Yang, F De Marinis, J Bennouna, JH Kim, C Chouaid, R Wiewrodt, F Grossi, J Feng, J Strausz, S Lu, DW Kim, X Liu, YM Chen, C Zhou, B Wang, VK Chand, K Park · Pneumologie · 2015 · Heft 02
Bibliografische Angaben
Zusammenfassung
Background: Continuation of EGFR inhibition beyond progression has been associated with improved disease control in case reports and retrospective/non-randomized studies. LL5 is a randomized trial, which assessed the efficacy of continuation of the irreversible ErbB family blocker, A, beyond progression with the addition of P in NSCLC pts with prior benefit from reversible EGFR tyrosine kinase inhibitors (E/G) and A. Methods: In this open-label, global phase III trial, pts with NSCLC who had failed ≥1 line of CT and E/G (after ≥12 wks treatment) were treated with A (50 mg/day) in Part A (n= 1154). Upon progressi…
